Resveratrol induces apoptosis and alters gene expression in human fibrosarcoma cells

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 767-774

  Harati, Kamran ^a   Slodnik, Pawel ^a   Chromik, Ansgar Michael ^b   Goertz, Ole ^a   Hirsch, Tobias ^a   Kapalschinski, Nikolai ^a   Klein Hitpass, Ludger ^c   Kolbenschlag, Jonas ^a   Uhl, Waldemar ^b   Lehnhardt, Marcus ^a   Daigeler, Adrien ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Apoptosis; Chemotherapy; Doxorubicin; FACS; Fibrosarcoma; Gene expression; HT1080; Necrosis; Phytotherapy; Proliferation; Resveratrol; Soft tissue sarcoma; Taurolidine

Indexed keywords

RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; DNA MICROARRAY; DRUG EFFECTS; FIBROSARCOMA; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; HUMAN; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; FIBROSARCOMA; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STILBENES;

EID: 84923648983     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Hoos A, Lewis JJ and Brennan MF: [Soft tissue sarcoma: prognostic factors and multimodal treatment]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 71: 787-794, 2000.
2. Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. The Surgical clinics of North America 88: 629-646, viii, 2008.
3. Patrikidou A, Domont J, Cioffi A and Le Cesne A: Treating soft tissue sarcomas with adjuvant chemotherapy. Current treatment options in oncology 12: 21-31, 2011.
4. O'Brien GC, Cahill RA, Bouchier-Hayes DJ and Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci 175: 10-14, 2006.
5. Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G and Diggle P: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Seminars in dialysis 25: 233-238, 2012.
6. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C and Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112: 1585-1591, 2008.
7. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM and Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85: 389-395, 1999.
8. Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS and Romsdahl MM: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Annals of surgery 211: 476-481, 1990.
9. Donato Di Paola E and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4): S138-141, 2002.
10. Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematology/oncology clinics of North America 20: 401-429, 2006.
11. Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Potter R, Kotz R and Zielinski CC: Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 4: 151-160, 2000.
12. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D and Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 19: 1238-1247, 2001.
13. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litiere S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP and van der Graaf WT: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. The lancet oncology 15: 415-423, 2014.
14. Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879, 2003.
15. Burningham Z, Hashibe M, Spector L and Schiffman JD: The epidemiology of sarcoma. Clinical sarcoma research 2: 14, 2012.
16. Burns J, Yokota T, Ashihara H, Lean ME, and Crozier A: Plant foods and herbal sources of resveratrol. Journal of agricultural and food chemistry 50: 3337-3340, 2002.
17. Renaud S and de Lorgeril M: The French paradox: dietary factors and cigarette smoking-related health risks. Annals of the New York Academy of Sciences 686: 299-309, 1993.
18. Carter LG, D'Orazio JA and Pearson KJ: Resveratrol and cancer: focus on in vivo evidence. Endocrine-related cancer 21: R209-225, 2014.
19. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP and Brenner DE: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16: 1246-1252, 2007.
20. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
21. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC and Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456-7463, 2001.
22. Chatterjee M, Das S, Janarthan M, Ramachandran HK and Chatterjee M: Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. European J Pharmacology 668: 99-106, 2011.
23. Alfaras I, Juan ME and Planas JM: trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. Journal of agricultural and food chemistry 58: 8104-8110, 2010.
24. Dias SJ, Li K, Rimando AM, Dhar S, Mizuno CS, Penman AD and Levenson AS: Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. The Prostate 73: 1135-1146, 2013.
25. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr. and Sledge GW Jr.: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Molecular Cellular Biology 17: 3629-3639, 1997.
26. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clinical cancer research: an official journal of the American Association for Cancer Research 5: 119-127, 1999.
27. Wang CY, Mayo MW and Baldwin AS Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
28. Duckett CS: Apoptosis and NF-kappa B: the FADD connection. J Clin Invest 109: 579-580, 2002.
29. Park JM, Kim A, Oh JH and Chung AS: Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis 28: 837-847, 2007.
30. Harati K, Chromik AM, Bulut D, Goertz O, Hahn S, Hirsch T, Klein-Hitpass L, Lehnhardt M, Uhl W and Daigeler A: TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells. Anticancer Res 32: 2967-2984, 2012.
31. Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P and Bifulco M: The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacological research: the official journal of the Italian Pharmacological Society 65: 365-371, 2012.
32. Qi M, Yao G, Fan S, Cheng W, Tashiro S, Onodera S and Ikejima T: Pseudolaric acid B induces mitotic catastrophe followed by apoptotic cell death in murine fibrosarcoma L929 cells. European J Pharmacology 683: 16-26, 2012.
33. Lee SJ and Kim MM: Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sciences 88: 465-472, 2011.
34. Soleas GJ, Goldberg DM, Grass L, Levesque M and Diamandis EP: Do wine polyphenols modulate p53 gene expression in human cancer cell lines? Clinical Biochemistry 34: 415-420, 2001.
35. Clement MV, Hirpara JL, Chawdhury SH and Pervaiz S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92: 996-1002, 1998.
36. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr. and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug metabolism and disposition: the biological fate of chemicals 32: 1377-1382, 2004.
37. Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, Mittelkotter U, Uhl W and Chromik AM: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. Journal of experimental & clinical cancer research: CR 27: 82, 2008.
38. Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, Muller R, Meese E and Lenhof HP: GeneTrail - advanced gene set enrichment analysis. Nucleic Acids Res 35: W186-192, 2007.
39. Al-Harthi SE, Alarabi OM, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Khan LM and Osman AM: Amelioration of doxorubicininduced cardiotoxicity by resveratrol. Molecular medicine reports 10: 1455-1460, 2014.
40. Arafa MH, Mohammad NS, Atteia HH and Abd-Elaziz HR: Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. Journal of Physiology and Biochemistry 70: 701-711, 2014.
41. Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. International J Oncology 12: 865-869, 1998.
42. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M and Workman P: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840-5850, 2007.
43. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Current Oncology Reports 14: 129-138, 2012.
44. Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR and Duan Z: Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PloS one 9: e93996, 2014.
45. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP and Cordon-Cardo C: The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine 13: 748-753, 2007.
46. Cheung M and Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Current Cancer Drug Targets 13: 234-244, 2013.
47. Rios-Moreno MJ, Jaramillo S, Diaz-Delgado M, Sanchez-Leon M, Trigo-Sanchez I, Padillo JP, Amerigo J and Gonzalez-Campora R: Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res 31: 3019-3025, 2011.
48. Shaw LM: Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Molecular and Cellular Biology 21: 5082-5093, 2001.
49. Song JJ, Kim JH, Sun BK, Alcala MA Jr., Bartlett DL and Lee YJ: c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cellular Signalling 22: 377-385, 2010.
50. Ito S, Koshikawa N, Mochizuki S and Takenaga K: 3-Methyladenine suppresses cell migration and invasion of HT1080 fibrosarcoma cells through inhibiting phosphoinositide 3-kinases independently of autophagy inhibition. International J Oncol 31: 261-268, 2007.
51. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, Faircloth G and Bertino JR: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clinical cancer research: an official journal of the American Association for Cancer Research 7: 2908-2911, 2001.
52. Ware PL, Snow AN, Gvalani M, Pettenati MJ and Qasem SA: MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. American J Clinical Pathology 141: 334-341, 2014.
53. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL and Bui BN: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The Lancet Oncology 13: 1133-1140, 2012.
54. Guled M, Pazzaglia L, Borze I, Mosakhani N, Novello C, Benassi MS and Knuutila S: Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis. Genes, Chromosomes & Cancer 53: 693-702, 2014.
55. Panagopoulos I, Bjerkehagen B, Gorunova L, Berner JM, Boye K, and Heim S: Several fusion genes identified by whole transcriptome sequencing in a spindle cell sarcoma with rearrangements of chromosome arm 12q and MDM2 amplification. International J Oncology 45: 1829-1836, 2014.
56. Schmidt H, Taubert H, Wurl P, Kappler M, Lange H, Bartel F, Bache M, Holzhausen HJ, and Hinze R: Gains of 12q are the most frequent genomic imbalances in adult fibrosarcoma and are correlated with a poor outcome. Genes, Chromosomes & Cancer 34: 69-77, 2002.
57. Shouda T, Hiraoka K, Komiya S, Hamada T, Zenmyo M, Iwasaki H, Isayama T, Fukushima N, Nagata K, and Yoshimura A: Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer letters 231: 176-184, 2006.
58. Yan S, Li Z and Thiele CJ: Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Oncotarget 4: 433-445, 2013.
59. Li N, Grivennikov SI and Karin M: The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19: 429-431, 2011.
60. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ: Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117: 5701-5709, 2011.
61. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. Journal of Neuro-oncology 101: 393-403, 2011.
62. Teng Y, Xie X, Walker S, White DT, Mumm JS and Cowell JK: Evaluating human cancer cell metastasis in zebrafish. BMC cancer 13: 453, 2013.
63. Shor AC, Agresta SV, D'Amato GZ and Sondak VK: Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer control: journal of the Moffitt Cancer Center 15: 47-54, 2008.
64. Herr MJ, Mabry SE, Jameson JF and Jennings LK: Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor. Biochemical and Biophysical Research Communications 442: 99-104, 2013.